Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups
about
Meta-analysis of proportion estimates of Extended-Spectrum-Beta-Lactamase-producing Enterobacteriaceae in East Africa hospitalsThe Problem of Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae DetectionThe β-Lactams Strike Back: Ceftazidime-AvibactamTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsTrends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) programAn extracorporeal blood-cleansing device for sepsis therapy.In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.Carbapenemase-producing Enterobacteriaceae.In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactamβ-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates.Carbapenem-Resistant Enterobacteriaceae Infections in Children.The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis.Escherichia coli sequence type 131: epidemiology and challenges in treatment.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review.Colonization and infection with extended-spectrum beta-lactamase producing Enterobacteriaceae in patients with malignancy.Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.Detection of bla KPC-2 in Proteus mirabilis in Brazil.Carbapenem-Resistant Enterobacteriaceae.Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study.In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014Reducing Uncertainty for Acute Febrile Illness in Resource-Limited Settings: The Current Diagnostic Landscape.Multiple Renal Abscesses due to ESBL Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Causing Acute Pyelonephritis and Bacteremia: A Case Report with a Good Outcome (No Drainage Required).Structure and Functional Characterisation of a Distinctive β-Lactamase from an Environmental Strain EMB20 of Bacillus cereus.High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
P2860
Q26749161-8F0CA7FF-B52A-4659-832E-76EAFB479B66Q26770418-EE6970D5-985B-40C9-B024-25400019CC58Q26796425-8E345E94-E95A-4EEB-B233-74E7A6CB7342Q28082546-4AC1343B-7784-48E7-AEE4-944C7D8CBEE0Q30914624-1DEA2151-B9A3-4306-BC17-848F60040EF1Q34174397-39C77557-956D-40EE-AFB4-E3D9D3AAEEAEQ34438255-40A32D35-3BEC-4DF7-B110-B85F1BEA2B0BQ34596516-60C08A1B-AAAB-46CF-9E4F-947DA67CE7AAQ35555196-7D2D0475-3BA3-4619-B9AD-ECBFF3F352FDQ35556737-404C34C8-ADAC-463C-B7B2-8922CCA198BEQ35607885-C6CA4C35-DF9F-4B03-8259-58E54DC43743Q35751615-59EE97BD-890B-4D4F-8019-E376A74AA0FBQ36290482-A2F5A138-1AEB-4535-A6A3-084922377FF8Q36644679-009F7992-F920-415A-B45A-A015876978F3Q36644786-459A1F04-A01E-447B-B17F-97F40D09E8A0Q36887866-59867D48-4D98-4566-96CA-22E7EB4D4ECBQ36888062-4639EA37-5BD2-4120-A9D3-C071B5FA0487Q37023324-FAA08AC7-0011-4553-ACD1-6CA12901F721Q37120191-83ACD182-F2AF-4500-870D-B07CBA95A900Q37154718-296E7222-3BC5-44C7-A820-34BA55974FB5Q37400286-297764EF-A482-47A0-B555-CE8B530953F1Q38201515-379A326D-262B-4B81-AB6F-4E036D57B87FQ38222497-34DB3806-62E8-4EC5-9A7F-2C09D5E8427AQ38325959-90B4F0DA-7524-4FA4-8589-DE92D53C219EQ38595451-E1BAA2B4-583B-4A72-B479-3E89F375A659Q38620812-8C9B167D-F7C7-4F7D-B598-97DE982B4207Q38652231-6B80B892-AFDA-4D9E-9CF9-8B4F782F8324Q38665505-891B0915-3A1C-4647-9323-74F6763CE032Q38793981-E252354D-D448-4D39-9AD3-8347317F9CF2Q38797485-BD9F2ABC-44F5-489C-AE1E-C3C07F74D7B8Q38875315-04ADFE74-076C-428B-84FD-4C929909514DQ38901844-E91ED5D7-49AC-496A-B3CD-0F1B0FFBC669Q38928329-40761BA9-F343-4A2A-A941-2D075F48697FQ39273184-32D000BE-3A60-40A3-8343-9F7A87B379C2Q39284005-4D4ECEDA-4947-49A7-94F5-D3C9937471BFQ39515520-8E4B40E1-4451-4BB4-B99E-DB5B3DA32BA9Q40047757-A4AB2EE3-61A4-4CA2-9CA8-6C94EF63ACEFQ40075168-288C3335-EB9A-494F-A70D-464F7654AB9BQ40152739-E9621441-8334-4000-8BDA-C4A6182C606FQ40282001-58DD990C-82A7-4224-9C81-38F5BDCB51CB
P2860
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Contemporary diversity of β-la ...... t prevalent β-lactamase groups
@en
type
label
Contemporary diversity of β-la ...... t prevalent β-lactamase groups
@en
prefLabel
Contemporary diversity of β-la ...... t prevalent β-lactamase groups
@en
P2093
P2860
P356
P1476
Contemporary diversity of β-la ...... t prevalent β-lactamase groups
@en
P2093
Kevin M Krause
Ronald N Jones
Sarah E Farrell
P2860
P304
P356
10.1128/AAC.01896-13
P407
P577
2013-11-18T00:00:00Z